NSE · Healthcare · Diagnostics & Research
EPS came in at 0.91 against a street estimate of 1.26 — a miss of 27.8%.
with an average price target of ₹510.00.
MIXED Q2 showed sequential recovery, with revenue up 13% and EBITDA margin at 18%, but revenue remained below last year and Discovery declined. Management maintained mid-20s FY27 EBITDA margin guidance, while hedge losses and Bayview’s long ramp remain risks. Q2 FY27 India will conduct process development for the Bayview program; U.S. drug-substance manufacturing is expected to begin in FY28, subject to approvals. Analysts pressed management on reorganization, Discovery weakness, Bayview utilization and margin sustainability. Management emphasized early recovery, continued cost actions and a longer transition toward differentiated offerings. 2026-10-28…
Full summary in the app.
| Holder | Stake |
|---|---|
| Nippon Life India Trustee Ltd-a/c Nippon India Pha | 8.00% |
| ICICI Prudential Mnc Fund | 6.82% |
| DSP Nifty 500 Index Fund | 4.71% |
| SBI Nifty Smallcap 250 ETF | 3.10% |
| Life Insurance Corporation of India | 1.78% |
| Document | Date |
|---|---|
| Q1 FY27 earnings call | 2026-08-06 |
| Investor presentation SYNGENE INTERNATIONAL LIMITED – INVESTOR SUMMARY Q1 FY27 (Quarter ended June 30, 2026) --- HEADLINE NUMBERS • Revenue from Operations: Rs 736 Cr, d | 2026-07-29 |
| Annual report FY2026 SYNGENE INTERNATIONAL LIMITED – FY 2025-26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from operations: Rs 37,387 Mn (3% year-on-year gr | 2026-07-02 |
| Q4 FY26 earnings call DOCUMENT SUMMARY: SYNGENE INTERNATIONAL LIMITED IMPORTANT NOTE This document is a regulatory filing notice only – it merely intimates that an earning | 2026-05-04 |
| Investor presentation · Q4 FY26 SYNGENE INTERNATIONAL LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue from Operations: Rs 3,739 Cr (~USD 419 Mn), grew 3% year-on-year • | 2026-04-30 |
| Quarterly results · Q4 FY26 SYNGENE INTERNATIONAL LIMITED - INVESTOR SUMMARY HEADLINE NUMBERS • FY 2025-26 Standalone Revenue from Operations: Rs. 34,238 million (vs Rs. 33,733 | 2026-04-29 |
| Q3 FY26 earnings call SYNGENE INTERNATIONAL LIMITED – Q3 & 9M FY2026 SUMMARY HEADLINE NUMBERS • Q3 FY2026 Revenue: Rs.917 crores, down 3% year-on-year (down 7% in constan | 2026-01-29 |
| Investor presentation · Q3 FY26 SYNGENE INTERNATIONAL LIMITED – INVESTOR SUMMARY January 2026 Investor Presentation --- HEADLINE NUMBERS • Q3 FY26 Revenue from Operations: Rs 917 | 2026-01-23 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1.25 / share ex-date Jun 25, 2026 · record Jun 26, 2026 | 2026-06-25 |
| Announcement | Date |
|---|---|
| Acquisition announced by Syngene International Limited Syngene International Limited, a pharmaceutical/biotech company, has announced an investment of Rs. 2.52 crores (Rs. 25.2 million) in Ampin C&I Power Twelve Private Limited, a newly formed r | 2026-08-24 |
| Acquisition announced Syngene International Limited has informed the Exchange about Acquisition | 2025-12-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Syngene International Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.